You are here: Home > Cell Lines
Choose a sub category:
Human Breast Cancer
Human Hematopoetic Malignancies
Human Pancreatic Cancer
Human Prostate Cell Lines
Cell Lines
 

Academic discount available for Cell Lines ONLY.

 

All of the cell lines available from Asterand were developed in conjunction with different academic institutions.  As a result of our agreements with these institutions, we offer our cell lines to academic and governmental researchers and non-profit research organizations at prices lower than those available to our commercial customers. To enroll in the Academic Pricing Program please email us with your name and shipping address at academics@asterand.com. We’ll reply to you with an account password, enabling you to view our products and prices available through this program. In the meantime, we encourage you to browse the site for more product information.
 

All cell lines are provided in ampoules of ~1x106 cells.

KCI-MOH1
Our Price: $7,000.00

KCI-MOH1, a human pancreatic tumor cell line, was derived from a xenograft model of adenocarcinoma of the pancreas.
MCF10DCIS.com
Our Price: $7,000.00

MCF10DCIS.com is a clonal breast cancer cell line. Pre-malignant MCF10AT cells were injected into severe combined immunodeficient (SCID) mice, resulting in tumor growth. The DCIS.com line was cloned from cell culture of this xenograft. Injection of the MCF10DCIS.com cells into SCID mice results in rapidly growing lesions that are predominantly comedo DCIS.  The tumor mass of these tumors is composed of tightly packed tubular structures, many with central necrosis.

OPCN-1
Our Price: $7,000.00


OPCN-1:  Derived from normal prostate epithelium from patient with prostate cancer (T1cN0M0; Gleason 3+3). Patient received no chemotherapy, no radiotherapy and no hormone treatment.

OPCN-2
Our Price: $7,000.00


OPCN-2:  Derived from normal prostate epithelium from patient with prostate cancer (PT2aN0M0; Gleason 2+3). Patient received no chemotherapy, radiation or hormone treatment. 
OPCN-3
Our Price: $7,000.00


OPCN-3: Derived from normal prostate epithelium from patient with prostate cancer (T3aN0M0; Gleason 2+2). Patient received no chemotherapy, radiation or hormone treatment.
OPCT-1
Our Price: $7,000.00


OPCT-1: Derived from prostate tumor epithelium (T1cN0M0, Gleason 3+3) Patient received no chemotherapy, no radiotherapy and no hormone treatment.
OPCT-2
Our Price: $7,000.00


OPCT-2: Derived from prostate tumor epithelium (PT2aN0M0; Gleason 2+3). Patient received no chemotherapy, radiation or hormone treatment.
OPCT-3
Our Price: $7,000.00


OPCT-3: Derived from prostate tumor epithelium (T3aN0M0; Gleason 2+2). Patient received no chemotherapy, radiation or hormone treatment.
SUM-102PT
Our Price: $7,000.00

Developed from a patient ultimatley diagnosed with extensive ductal carcinoma in situ with areas of micro-invasion. This specimen was obtained following completion of neo-adjuvant chemotherapy.
SUM-1315MO2
Our Price: $7,000.00

A cell line developed from a mouse xenograft derived by transplantation of a metastatic nodule of a patient with infiltrating ductal carcinoma.
SUM-149PT
Our Price: $7,000.00

Derived from a primary inflammatory ductal carcinoma of the breast from a patient with locally advanced disease.
SUM-159PT
Our Price: $7,000.00

A cell line isolated from a primary tumor of a patient with anaplastic carcinoma of the breast.
SUM-185PE
Our Price: $7,000.00

Derived from pleural effusion obtained from a patient with ductal carcinoma of the breast. Cytological examination of the effusion specimen confirmed the presence of carcinoma cells in the specimen.
SUM-190PT
Our Price: $7,000.00

Derived from a poorly differentiated inflammatory breast carcinoma. The cancer cells were ER and PR negative by immunohistochemistry.
SUM-225CWN
Our Price: $7,000.00

Derived from a chest wall recurrence in a patient diagnosed and treated six years previously for ductal carcinoma in situ. The chest wall specimen was positive for adenocarcinoma.
SUM-229PE
Our Price: $7,000.00

The SUM-229PE cell line was derived from pleural effusion obtained from a patient with ER negative breast cancer.
SUM-44PE
Our Price: $7,000.00

Developed from a pleural effusion from a patient with ER positive breast cancer.
SUM-52PE
Our Price: $7,000.00

Developed from a pleural effusion from a patient with ER negative breast cancer.
WSU-AML
Our Price: $7,000.00


WSU-AML, a new human aggressive AML cell line, was established from frozen peripheral blood of a patient with AML. The cell line showed a partial interstitial deletion of the long arm (q) of chromosome 9.  Phenotypically, the cell line is consistent with a diagnosis of M7 AML.

WSU-DLCL2
Our Price: $7,000.00


WSU-DLCL2, a human diffuse large cell lymphoma cell line, is a mature B-cell line (IgG l) that is negative for EBV nuclear antigen, expresses the multi-drug resistance phenotype, and has t (14;18) (q32;q21) plus other chromosomal aberrations.
WSU-FSCCL
Our Price: $7,000.00


WSU-FSCCL, a human B-cell line, was established from an EBV-negative low-grade follicular small cleaved cell Lymphoma in leukemic phase.

WSU-NHL
Our Price: $7,000.00


WSU-NHL was established from a malignant pleural effusion occurring in a patient with nodular histiocytic (follicular, large cell) lymphoma.

WSU-Pre-B-ALL
Our Price: $7,000.00


WSU-Pre-B-ALL, a new human EBV negative pre-B-Acute Lymphoblastic Leukemia, was established from frozen peripheral blood of a patient with ALL in leukemic phase.  Both the frozen cells and the established cell line exhibit t (1;19) chromosomal translocation, partial deletion of the short arm (p) of chromosome 9 and a loss of chromosome 13 as clonal abnormalities.
WSU-WM
Our Price: $7,000.00


WSU-WM was established from pleural effusion from a patient with IgMk Waldenstrom?s macroglobulinemia (WM) which is a human B-cell tumor.